Darmstadt, Germany, September 18, 2014 – Merck KGaA, Darmstadt, Germany, today announced that the Board of Partners has promoted Stefan Oschmann (57) to the position of Deputy CEO and Vice Chairman of the Executive Board. Concurrently, BelÚn Garijo (54) was appointed to the Executive Board to take over leadership for the Pharma business. The management changes will become effective as of January 1, 2015.
Oschmann, currently CEO Pharma, will represent Karl-Ludwig Kley, Chairman of the Executive Board. Both will share strategic management functions and will represent the company with politicians and international organizations.
As a member of the Executive Board, Garijo, currently CEO of the company’s biopharmaceutical division, will take on responsibility for the whole Pharma business. Besides the biopharmaceutical division, this includes Consumer Health, Allergy and Biosimilars.
“With today’s management decisions we strengthen our leadership team and prepare the ground for continuity to reach our ambitious growth targets until the year 2018 and beyond,” said Johannes Baillou, Chairman of the Board of Partners of E. Merck KG, Darmstadt, Germany. “Stefan Oschmann who has successfully reorganized our pharma businesses over the past years will familiarize himself with Group-wide functions and will increasingly assume external responsibilities for the company. BelÚn Garijo has many years of experience in the pharma industry, has proven that she can further develop our business organization and in her future role will provide a significant contribution to ensure the sustainable success of our pharma businesses.”
Note to editors
You find pictures and CVs here.